Peer-influenced content. Sources you trust. No registration required. This is HCN.
Psych Congress Network
A single dose of an investigational LSD formulation was associated with greater improvement in depressive symptoms than placebo in a phase 3 trial of adults with major depressive disorder. The findings are based on topline company-reported results and await full peer-reviewed publication.
Psychiatry July 14th 2026
MDLinx
Primary care physicians increasingly inherit adult ADHD stimulant prescriptions amid specialist shortages and medication supply disruptions. Expert guidance highlights diagnostic verification, monitoring, and risk-assessment considerations without establishing a single standardized approach.
Family Medicine/General Practice July 14th 2026
Psychiatrist.com
Short-term benzodiazepine use after mass trauma was not associated with increased 12-month PTSD risk in a large retrospective cohort. Persistent use showed a different pattern, and the observational findings did not establish causality.
Conexiant
Viral claims described the ketogenic diet as a cure for schizophrenia despite limited supporting evidence. Available research consists of small pilot studies, while established treatment approaches continue to rely on pharmacologic and psychosocial interventions.
Psychiatry June 23rd 2026
A single 25-mg dose of synthetic psilocybin with structured psychological support produced rapid, large-magnitude reductions in suicidal ideation through 12 weeks in 20 treatment-resistant adults with major depressive disorder, with two participants experiencing worsening ideation.
Psychiatry June 9th 2026
“The amygdala’s response to social threat appears to feed into depressive symptoms much more strongly in young males than in young females.” — John Krystal, MD, Biological Psychiatry
Adolescent Medicine April 14th 2026